A new study suggests that KLRB1 gene inactivation or antibody-mediated KLRB1 blockade strengthens T cell-mediated killing of glioma cells in extracorporal and their antitumor function in vivo. This evidence concerns the gene KLRB1 and central nervous system cancer.